Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted Psychotherapy for Demoralization in Advanced Cancer
NCT06818994Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in demoralization syndrome. Primary endpoints: Demoralization Scale at 19 weeks and Adverse Events and Serious Adverse Events at 19 weeks. Started Apr 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
demoralization syndrome
Beyond the preview
Go deeper on NCT06818994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818994.